Summary & Overview
HCPCS Level II J0587: Rimabotulinumtoxinb Injection, 100 Units
HCPCS Level II code J0587 denotes a 100-unit vial of rimabotulinumtoxinb for injection, an FDA-approved botulinum toxin product used in therapeutic settings. Nationally, accurate coding for injectable biologics such as rimabotulinumtoxinb matters for clinical documentation, claims processing, and consistent payment for complex outpatient treatments. This code identifies the specific product and unit quantity, supporting precise billing across care settings where injections are delivered.
Key payers analyzed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on how the code is used in practice, typical sites of service, and the payer landscape relevant to this injectable biologic. The publication summarizes available benchmarks and policy considerations affecting coverage and billing for biologic injections, clarifies common clinical contexts in which rimabotulinumtoxinb is administered, and highlights areas where coding accuracy affects reimbursement and utilization reporting.
The document is intended for billing professionals, practice managers, and policy analysts seeking a national overview of HCPCS Level II code J0587, its clinical role, and the payer environment. Data not provided in the source input are noted where applicable.
Billing Code Overview
HCPCS Level II code J0587 describes Injection, rimabotulinumtoxinb, 100 units. The service represents a parenteral therapeutic biologic administered by injection. The service type is an injectable botulinum toxin preparation used for therapeutic indications that require rimabotulinumtoxinb dosing. The typical site of service is an outpatient clinic or physician office, ambulatory surgical center, or hospital outpatient department where injectable biologic therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient neurology or pain management clinic with focal spasticity or dystonia refractory to oral therapies. After a diagnostic evaluation including history and focused neurologic exam, the clinician documents muscle groups targeted for chemodenervation. The patient is consented for J0587 (rimabotulinumtoxinb, 100 units) with discussion of expected effects, onset, duration, and potential adverse events. The procedure is performed in a procedure room or clinic exam room (office outpatient setting) with the patient seated or supine; sterile technique is used. Localization may be by palpation, EMG, or ultrasound depending on the provider. The clinician prepares the appropriate dilution of rimabotulinumtoxinb, draws specified units into syringes, and injects into designated muscles at multiple sites per clinical protocol. Post-injection monitoring for immediate adverse reaction is completed for a short observation period. Documentation includes indication, informed consent, medication lot number and expiration, units administered, injection sites, technique (EMG/ultrasound if used), and any adverse events. Billing uses J0587 with appropriate modifier(s) to reflect service circumstances and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier required / not otherwise specified |